{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:39:07Z","timestamp":1778837947246,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T00:00:00Z","timestamp":1508976000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Department of Science and Techonology, India","award":["SR\/WOS-A\/LS-126\/2014"],"award-info":[{"award-number":["SR\/WOS-A\/LS-126\/2014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s10238-017-0478-x","type":"journal-article","created":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T07:33:36Z","timestamp":1509003216000},"page":"221-227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["High mTOR expression independently prognosticates poor clinical outcome to induction chemotherapy in acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"18","author":[{"given":"Asheema","family":"Khanna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharat","family":"Bhushan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradeep Singh","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunita","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipendra Kumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7643-7936","authenticated-orcid":false,"given":"Fouzia","family":"Siraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,26]]},"reference":[{"key":"478_CR1","first-page":"1","volume-title":"Global cancer facts and figures","author":"M Center","year":"2011","unstructured":"Center M, Siegel R, Jemal A. Global cancer facts and figures. Atlanta: American Cancer Society; 2011. p. 1\u201352."},{"issue":"1","key":"478_CR2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0272-2712(18)30073-8","volume":"20","author":"DC Farhi","year":"2000","unstructured":"Farhi DC, Rosenthal NS. Acute lymphoblastic leukemia. Clin Lab Med. 2000;20(1):17\u201328.","journal-title":"Clin Lab Med"},{"issue":"5","key":"478_CR3","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","volume":"29","author":"R Bassan","year":"2011","unstructured":"Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5):532\u201343. doi: 10.1200\/JCO.2010.30.1382 .","journal-title":"J Clin Oncol"},{"issue":"2","key":"478_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1056\/NEJMra052603","volume":"354","author":"CH Pui","year":"2006","unstructured":"Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166\u201378. doi: 10.1056\/NEJMra052603 .","journal-title":"N Engl J Med"},{"issue":"4","key":"478_CR5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.4103\/0971-5851.125245","volume":"34","author":"A Mukhopadhyay","year":"2013","unstructured":"Mukhopadhyay A, Gangopadhyay S, Dasgupta S, Paul S, Mukhopadhyay S, Ray UK. Surveillance and expected outcome of acute lymphoblastic leukemia in children and adolescents: an experience from Eastern India. Indian J Med Paediatr Oncol. 2013;34(4):280. doi: 10.4103\/0971-5851.125245 .","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"2","key":"478_CR6","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.3390\/ijms13021886","volume":"13","author":"H P\u00f3pulo","year":"2012","unstructured":"P\u00f3pulo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci. 2012;13(2):1886\u2013918. doi: 10.3390\/ijms13021886 .","journal-title":"Int J Mol Sci"},{"issue":"16","key":"478_CR7","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1101\/gad.1212704","volume":"18","author":"N Hay","year":"2004","unstructured":"Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18(16):1926\u201345. doi: 10.1101\/gad.1212704 .","journal-title":"Genes Dev"},{"issue":"392","key":"478_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.canlet.2017.01.035","volume":"28","author":"M Gazi","year":"2017","unstructured":"Gazi M, Moharram SA, Marh\u00e4ll A, Kazi JU. The dual specificity PI3K\/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL). Cancer Lett. 2017;28(392):9\u201316. doi: 10.1016\/j.canlet.2017.01.035 .","journal-title":"Cancer Lett"},{"issue":"79","key":"478_CR9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.biocel.2016.09.006","volume":"31","author":"M Granato","year":"2016","unstructured":"Granato M, Rizzello C, Romeo MA, et al. Concomitant reduction of c-Myc expression and PI3K\/AKT\/mTOR signaling by quercetin induces a strong cytotoxic effect against Burkitt\u2019s lymphoma. Int J Biochem Cell Biol. 2016;31(79):393\u2013400. doi: 10.1016\/j.biocel.2016.09.006 .","journal-title":"Int J Biochem Cell Biol"},{"issue":"3","key":"478_CR10","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/leu.2012.276","volume":"27","author":"MR Janes","year":"2013","unstructured":"Janes MR, Vu C, Mallya S, et al. Efficacy of the investigational mTOR kinase inhibitor MLN0128\/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia. 2013;27(3):586\u201394. doi: 10.1038\/leu.2012.276 .","journal-title":"Leukemia"},{"issue":"1","key":"478_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3324\/haematol.2010.026997","volume":"96","author":"P Saunders","year":"2011","unstructured":"Saunders P, Cisterne A, Weiss J, Bradstock KF, Bendall LJ. The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia. Haematologica. 2011;96(1):69\u201377. doi: 10.3324\/haematol.2010.026997 .","journal-title":"Haematologica"},{"issue":"1","key":"478_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-016-0241-x","volume":"9","author":"PJ Shi","year":"2016","unstructured":"Shi PJ, Xu LH, Lin KY, Weng WJ, Fang JP. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia. J Hematol Oncol. 2016;9(1):12. doi: 10.1186\/s13045-016-0241-x .","journal-title":"J Hematol Oncol"},{"issue":"4","key":"478_CR13","doi-asserted-by":"publisher","first-page":"e59335","DOI":"10.1371\/journal.pone.0059335","volume":"8","author":"K Nemes","year":"2013","unstructured":"Nemes K, Sebesty\u00e9n A, M\u00e1rk \u00c1, et al. Mammalian target of rapamycin (mTOR) activity dependent phospho-protein expression in childhood acute lymphoblastic leukemia (ALL). PLoS ONE. 2013;8(4):e59335. doi: 10.1371\/journal.pone.0059335 .","journal-title":"PLoS ONE"},{"issue":"4","key":"478_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.5114\/wo.2016.61848","volume":"20","author":"E Uli\u0144ska","year":"2016","unstructured":"Uli\u0144ska E, Mycko K, Sa\u0142aci\u0144ska-\u0141o\u015b E, et al. Impact of mTOR expression on clinical outcome in paediatric patients with B-cell acute lymphoblastic leukaemia\u2013preliminary report. Contemp Oncol. 2016;20(4):291. doi: 10.5114\/wo.2016.61848 .","journal-title":"Contemp Oncol"},{"issue":"1","key":"478_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10238-009-0067-8","volume":"10","author":"B Bhushan","year":"2010","unstructured":"Bhushan B, Chauhan PS, Saluja S, et al. Aberrant phenotypes in childhood and adult acute leukemia and its association with adverse prognostic factors and clinical outcome. Clin Exp Med. 2010;10(1):33\u201340. doi: 10.1007\/s10238-009-0067-8 .","journal-title":"Clin Exp Med"},{"issue":"4","key":"478_CR16","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2014\u0394\u0394CT method. Methods. 2001;25(4):402\u20138. doi: 10.1006\/meth.2001.1262 .","journal-title":"Methods"},{"issue":"1","key":"478_CR17","first-page":"186","volume":"8","author":"NC Cross","year":"1994","unstructured":"Cross NC, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia. 1994;8(1):186\u20139.","journal-title":"Leukemia"},{"issue":"7","key":"478_CR18","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa035091","volume":"349","author":"CH Pui","year":"2003","unstructured":"Pui CH, Cheng C, Leung W, et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med. 2003;349(7):640\u20139. doi: 10.1056\/NEJMoa035091 .","journal-title":"N Engl J Med"},{"issue":"4","key":"478_CR19","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1182\/blood-2006-07-038299","volume":"110","author":"JB Nachman","year":"2007","unstructured":"Nachman JB, Heerema NA, Sather H, et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood. 2007;110(4):1112\u20135. doi: 10.1182\/blood-2006-07-038299 .","journal-title":"Blood"},{"issue":"7","key":"478_CR20","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/0145-2126(85)90315-7","volume":"9","author":"DM Kamat","year":"1985","unstructured":"Kamat DM, Gopal R, Advani SH, et al. Pattern of subtypes of acute lymphoblastic leukemia in India. Leuk Res. 1985;9(7):927\u201334. doi: 10.1016\/0145-2126(85)90315-7 .","journal-title":"Leuk Res"},{"issue":"8","key":"478_CR21","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/0145-2126(88)90102-6","volume":"12","author":"M Bhargava","year":"1988","unstructured":"Bhargava M, Kumar R, Karak A, Kochupillai V, Arya LS, Mohanakumar T. Immunological subtypes of acute lymphoblastic leukemia in North India. Leuk Res. 1988;12(8):673\u20138. doi: 10.1016\/0145-2126(88)90102-6 .","journal-title":"Leuk Res"},{"issue":"9","key":"478_CR22","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1084\/jem.20110121","volume":"208","author":"H Medyouf","year":"2011","unstructured":"Medyouf H, Gusscott S, Wang H, et al. High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. J Exp Med. 2011;208(9):1809\u201322. doi: 10.1084\/jem.20110121 .","journal-title":"J Exp Med"},{"issue":"4","key":"478_CR23","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1182\/blood-2011-12-389932","volume":"120","author":"SK Tasian","year":"2012","unstructured":"Tasian SK, Doral MY, Borowitz MJ, et al. Aberrant STAT5 and PI3\u00a0K\/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. Blood. 2012;120(4):833\u201342. doi: 10.1182\/blood-2011-12-389932 .","journal-title":"Blood"},{"issue":"1","key":"478_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40364-016-0080-5","volume":"4","author":"Z Jiang","year":"2016","unstructured":"Jiang Z, Wu D, Lin S, Li P. CD34 and CD38 are prognostic biomarkers for acute B lymphoblastic leukemia. Biomark Res. 2016;4(1):23. doi: 10.1186\/s40364-016-0080-5 .","journal-title":"Biomark Res"},{"issue":"1","key":"478_CR25","first-page":"31","volume":"82","author":"N Cascavilla","year":"1997","unstructured":"Cascavilla N, Musto P, D\u2019Arena GI, Ladogana S, Matera R, Carotenuto M. Adult and childhood acute lymphoblastic leukemia: clinico-biological differences based on CD34 antigen expression. Haematologica. 1997;82(1):31\u20137.","journal-title":"Haematologica"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10238-017-0478-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-017-0478-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-017-0478-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T01:40:03Z","timestamp":1570239603000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10238-017-0478-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,26]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["478"],"URL":"https:\/\/doi.org\/10.1007\/s10238-017-0478-x","relation":{},"ISSN":["1591-8890","1591-9528"],"issn-type":[{"value":"1591-8890","type":"print"},{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,26]]}}}